June 2026 in “International Journal of Drug Delivery Technology” The herbal hair oil is safe and may promote hair growth.
June 2026 in “Drug Delivery and Translational Research” The solid microneedle booster improves hair regrowth and follicle enrichment when used with minoxidil.
Most people with post-COVID syndrome experience symptoms like fatigue, but Omicron variants cause fewer persistent symptoms.
Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.
Hair regrowth improved, but quality of life did not.
STS01 1% effectively promotes hair regrowth with minimal side effects.
Long COVID symptoms are common and the new method will help test if remdesivir reduces them.
Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific doses and precautions.
Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific doses and precautions.
February 2026 in “Expert Opinion on Pharmacotherapy” Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific dosing and timing guidelines.
January 2026 in “Journal of Pharmacy & Bioresources” Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.
January 2026 in “Clinical Cosmetic and Investigational Dermatology” Early diagnosis and targeted anti-inflammatory treatments can improve outcomes in androgenetic alopecia with perifollicular inflammation and fibrosis.
December 2025 in “Cureus” Localized dystrophic epidermolysis bullosa (DEB) can lead to scarring alopecia, highlighting the need to recognize and address this complication.
November 2025 in “Cochrane Database of Systematic Reviews” Cyproterone acetate works similarly to other treatments for hirsutism, but more research is needed.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
October 2025 in “International Journal of Cosmetic Science” Shiny, straight hair is seen as more youthful, healthy, and attractive.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
July 2025 in “Dermatology Practical & Conceptual” Spironolactone is safe for treating hair loss in women without causing low blood pressure.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
May 2025 in “International Journal of Pharmacognosy and Chemistry” A new accurate and cost-effective method was developed to measure Minoxidil in different forms.
May 2025 in “Journal of Photochemistry and Photobiology B Biology” Blue LED light improves hair treatments for Caucasian and Asian hair but not for African hair.
April 2025 in “Physical and Engineering Sciences in Medicine” PCOS forum users view lifestyle changes and supplements positively, but have mixed feelings about contraceptive pills.
January 2025 in “PROTEOMICS” Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.
PRP can help regrow hair and improve hair transplant results.
January 2025 in “Faculty of 1000 Research Ltd” Plant-based treatments may help reduce BPH symptoms, but more research is needed.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
October 2024 in “JEADV Clinical Practice” UK dermatologists commonly use corticosteroids and minoxidil to treat hair loss conditions.
October 2024 in “Developmental Dynamics” Recent advances show zebrafish can model anemia, Alx4 affects craniofacial and hair development, and mTORC1 is crucial for retinal development.
August 2024 in “Skin Research and Technology” Low-dose oral minoxidil can help increase hair growth in women with hair loss.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.